type 2 diabetes, insulin therapy, adults, overweight, obesity, weight, glyceamic control, blood glucose, lifestyle, diabetes self management, cognitive behavioral therapy, liraglutide, GLP-1 type 2 diabetes, insuline therapie, volwassenen, overgewicht, obesitas, gewicht, glycemische controle, bloedglucose, bloedsuiker, leefstijl, diabetes zelfzorg, cognitieve gedragstherapie, liraglutide, GLP-1
Conditions
Interventions
The interventions are 26 weeks liraglutide or 26 weeks cognitive behavioral therapy added to insulin therapy and usual care.
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) analog that
Sponsors
Erasmus Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes and requiring insulin therapy (novorapid, novomix, levemir); 2. On maximal oral glucose lowering drugs; 3. BMI > 25 kg/m²; 4. GFR (renal function) > 60 µ mol/l; 5. Age 18-75; 6. Ability to speak Dutch or English.
Exclusion criteria
Exclusion criteria: 1. Eating disorder or major depression; 2. Alcohol abuse; 3. History of pancreatitis & thyroid disorders; 4. Inflammatory Bowel Syndrome; 5. Pregnancy or lactating; 6. Use of insulin; 7. Known allergy to Liraglutide; 8. Use of Liraglutide within 3 months before entering study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measure is weight change (kg). Mean weight change from baseline to month 6 in the liraglutide arm and CBT arm will be compared. In addition, weight change will be examined at month 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will examine the insulin consumption and the cost-effectiveness of both treatments. Furthermore, laboratory variables are measured to determine parameters of participants’ health during the study. In addition, diabetes specific psychological parameters are assessed to examine if CBT positively affects psychological well being. | — |
Contacts
Public ContactHanneke Buijks
Postbus 2040
Outcome results
None listed